ReviewMedicina (Kaunas, Lithuania)2021
Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.
Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Evaluation of clinicopathological features of renal biopsies in non-lupus rheumatic diseases: a university hospital experience.Renal failure · 2026Article
- Long-term clinical course of pediatric familial Mediterranean fever with heterozygous pathogenic MEFV exon 10 variants.European journal of pediatrics · 2026Article
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- Renal Amyloidosis in Pediatric Autoinflammatory Syndromes: Subclinical Onset, Early Biomarkers, and Clues for Timely Characterization and Interventions.Journal of clinical medicine · 2026Review
- Interleukin-6 Levels and Interleukin-6 rs1800795 Variant in Pediatric Familial Mediterranean Fever: Associations with Clinical Manifestations, Inflammatory Markers, and MEFV Mutation Status.Diagnostics (Basel, Switzerland) · 2026Article
- Evidence of the role of Midkine and Pleiotrophin in the pathogenesis of Familial Mediterranean Fever.European journal of pediatrics · 2026Article
- Amyloidosis secondary to familial Mediterranean fever: machine learning-based prediction models.Rheumatology (Oxford, England) · 2026Article
- The cally index as an indicator of inflammatory burden across clinical phases of familial mediterranean fever.Clinical rheumatology · 2026Article
- Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis.Kidney international · 2026Article
- KIM-1: A Non-Invasive Marker for Kidney Injury and Treatment Efficacy in FMF.Mediterranean journal of rheumatology · 2026Article
- Colchicine discontinuation in familial Mediterranean fever: short-term outcomes by pre-discontinuation attack frequency.Clinical rheumatology · 2026Article
- Comparative analysis of conventional and novel inflammatory biomarkers in Familial Mediterranean fever during attack-free periods.Advances in rheumatology (London, England) · 2025Article
- Review
- Rheumatologic and Autoimmune Features of Inborn Errors of Immunity: Implications for Diagnosis and Management.Journal of human immunity · 2025Article
- Evaluation of renal elasticity by shear wave elastography in children with Familial Mediterranean Fever.Pediatric nephrology (Berlin, Germany) · 2025Article
- Insights into familial Mediterranean fever: Chronic disease correlations with arthralgia and current health status of patients with familial Mediterranean fever in Jordan.Rheumatology and immunology research · 2025Article
- Increasing Importance of Genotype-Phenotype Correlations Associated with Common and Rare MEFV Gene Mutations in FMF Patients in the Last Thirty Years.Journal of clinical medicine · 2025Article
- Targeting interleukin-1 signaling for renoprotection.Frontiers in immunology · 2025Review
- Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms.Journal of clinical medicine · 2024Review
- Familial Mediterranean fever: perspective on female fertility and disease course in pregnancy from a multicenter nationwide network.Rheumatology international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF) is a genetic autoinflammatory disease with autosomal recessive transmission, characterized by periodic fever attacks with self-limited serositis. Secondary amyloidosis due to amyloid A renal deposition represents the most fearsome complication in up to 8.6% of patients. Amyloidosis A typically reveals a nephrotic syndrome with a rapid progression to end-stage kidney disease still. It may also involve the cardiovascular system, the gastrointestinal tract and the central nervous system. Other glomerulonephritis may equally affect FMF patients, including vasculitis such as IgA vasculitis and polyarteritis nodosa. A differential diagnosis among different primary and secondary causes of nephrotic syndrome is mandatory to determine the right therapeutic choice for the patients. Early detection of microalbuminuria is the first signal of kidney impairment in FMF, but new markers such as Neutrophil Gelatinase-Associated Lipocalin (NGAL) may radically change renal outcomes. Serum amyloid A protein (SAA) is currently considered a reliable indicator of subclinical inflammation and compliance to therapy. According to new evidence, SAA may also have an active pathogenic role in the regulation of NALP3 inflammasome activity as well as being a predictor of the clinical course of AA amyloidosis. Beyond colchicine, new monoclonal antibodies such as IL-1 inhibitors anakinra and canakinumab, and anti-IL-6 tocilizumab may represent a key in optimizing FMF treatment and prevention or control of AA amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.